Sandbox:skorjian2: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
‘’’Adjuvant therapy’’’
'''Adjuvant therapy'''
# Interferon alfa-2a (Roferon-A)
# Interferon alfa-2a (Roferon-A)
# Interferon alfa-2b (Intron-A)
# Interferon alfa-2b (Intron-A)
# Peginterferon alfa-2b (Sylatron)
# Peginterferon alfa-2b (Sylatron)


‘’’Metastatic or unresectable disease’’’
'''Metastatic or unresectable disease'''
:* ‘’’’’Single Agent Chemotherapy’’’’’
:* ''Single Agent Chemotherapy''
::# Dabrafenib (Tafinlar)
::# Dabrafenib (Tafinlar)
::# Dacarbazine (DTIC)
::# Dacarbazine (DTIC)
Line 20: Line 20:
::# Vemurafenib (Zelboraf)
::# Vemurafenib (Zelboraf)


:* ‘’’’’Combination Chemotherapy’’’’’
:* ''Combination Chemotherapy''
::# Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC)
::# Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC)
::# Carboplatin + Paclitaxel (CP)
::# Carboplatin + Paclitaxel (CP)

Revision as of 01:22, 22 August 2015

Adjuvant therapy

  1. Interferon alfa-2a (Roferon-A)
  2. Interferon alfa-2b (Intron-A)
  3. Peginterferon alfa-2b (Sylatron)

Metastatic or unresectable disease

  • Single Agent Chemotherapy
  1. Dabrafenib (Tafinlar)
  2. Dacarbazine (DTIC)
  3. Docetaxel (Taxotere)
  4. High-dose (HD) IL-2
  5. IL-2 maintenance biotherapy
  6. Imatinib (Gleevec)
  7. Ipilimumab (Yervoy)
  8. Nivolumab (Opdivo)
  9. Paclitaxel (Taxol)
  10. Pembrolizumab (Keytruda)
  11. Temozolomide (Temodar)
  12. Trametinib (Mekinist)
  13. Vemurafenib (Zelboraf)
  • Combination Chemotherapy
  1. Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC)
  2. Carboplatin + Paclitaxel (CP)
  3. Carboplatin + Paclitaxel + nanoparticle albumin-bound
  4. Carboplatin + Paclitaxe +, Sorafenib
  5. Cisplatin + Dacarbazine ± Carmustine
  6. Cisplatin + Dacarbazine + IL-2 + IFN alfa-2b ± Carmustine
  7. Cisplatin + Paclitaxel + Dacarbazine
  8. Cisplatin + Vinblastine + Dacarbazine (CVD)
  9. CVD + IL-2 + IFN alfa-2b (sequential biochemotherapy)
  10. Temozolomide + Bevacizumab (TB)
  11. Dabrafenib + Trametinib
  12. Ipilimumab + Dacarbazine
  13. Ipilimumab + Nivolumab